Abstract: The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphoma (ABC DLBCL) and autoimmune or inflammatory disorders.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
October 10, 2017
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Louis M. Staudt, Yibin Yang, Federico Bernal, Amanda L. Whiting
Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.
Type:
Grant
Filed:
August 7, 2013
Date of Patent:
October 3, 2017
Assignee:
POLYPHOR AG
Inventors:
Glenn E. Dale, Daniel Obrecht, Francesca Bernardini
Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, X, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
Type:
Grant
Filed:
October 10, 2016
Date of Patent:
September 26, 2017
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.
Type:
Grant
Filed:
December 11, 2014
Date of Patent:
September 19, 2017
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Inventors:
Kang-Yell Choi, Soung-Hoon Lee, Hyun-Yi Kim
Abstract: The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy.
Type:
Grant
Filed:
December 9, 2013
Date of Patent:
August 29, 2017
Assignee:
The Queen's University of Belfast
Inventors:
Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson
Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
August 22, 2017
Assignee:
ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.
Abstract: The present disclosure relates to a self-assembled peptide nanostructure including at least one amphiphilic peptide and a biosensor using the same. The amphiphilic peptide is a hairpin-shaped amphiphilic peptide including a hydrophilic domain having an ?-helical structure and a hydrophobic domain. The N-terminal of the hydrophobic domain is a pyrene group. Since the self-assembled peptide nanostructure is derived from an RNA, DNA or amino acid sequence capable of recognizing a specific target substance, it does not recognize other substances but exhibits high selectivity for the target substance. Specifically, since the self-assembled peptide nanostructure has an excimer fluorescence peak at 480 nm through binding with the target substance, it can be usefully used in medical applications such as diagnosis of diseases.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
August 15, 2017
Assignee:
Industry-Academic Cooperation Foundation, Yonsei University
Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin.
Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
Type:
Grant
Filed:
May 24, 2010
Date of Patent:
August 15, 2017
Assignees:
Lubris, LLC, Schepens Eye Research Institute
Inventors:
Benjamin Sullivan, Edward R. Truitt, David Sullivan
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Type:
Grant
Filed:
October 5, 2015
Date of Patent:
August 15, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.
Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
August 17, 2012
Date of Patent:
July 18, 2017
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
Abstract: A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion, the kinked portion comprising an endosomal-disrupting peptide. The peptide can include a peptide sequence of one of SEQ ID NOs: 1, 5-38, or 40-54 or 61-69. The conformationally-constrained kinked portion can be a majority portion or minority of the peptide.
Abstract: The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-?, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine.
Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
May 30, 2017
Assignee:
BIOM'UP
Inventors:
Christian Gagnieu, Patricia Forest, Sylvain Picot
Abstract: The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.
Abstract: The present invention provides a liposome based composition wherein the liposome includes a peptide conjugated thereto via a peptide bond, wherein the peptide includes a spacer amino acid and a short Apolipoprotein E recognition sequence or a short Amyloid beta recognition sequence. This invention further provides a process for making the liposome and methods of utilizing the liposome based composition for therapeutic and diagnostic purposes.
Type:
Grant
Filed:
November 19, 2013
Date of Patent:
May 23, 2017
Assignee:
Technion Research & Development Foundation Limited
Abstract: A therapeutic agent delivery system includes a therapeutic agent delivery platform and a therapeutic guest agent. The therapeutic agent delivery platform is capable of being implanted in a tissue being treated. The platform includes a substrate and at least one host molecule coupled to the substrate. The therapeutic guest agent is capable of reversibly coupling with the host molecule when administered to the tissue being treated. The reversible coupling is defined by the binding affinity between the host molecule and the therapeutic guest agent. The therapeutic guest agent is delivered at a rate determined by the affinity release rate between the host molecule and the therapeutic guest agent. The degradation rate of the therapeutic guest agent may be slower than the affinity release rate between the host molecule and the therapeutic guest agent.
Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.